Navigation Links
BRG1 mutations confer resistance to hormones in lung cancer
Date:3/15/2012

Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours is that their cells have lost the ability to differentiate; therefore these hormones have useful properties to prevent cancer. Currently, retinoic acid and steroids are being used to treat some types of leukaemia.

A study led by the research group on Genes and Cancer of the Bellvitge Biomedical Research Institute (IDIBELL) has shown that the loss of BRG1 gene implies a lack of response of cells to these hormones, and therefore the tumour may continue growing. Study results have been published in the journal EMBO Molecular Medicine.

BRG1 gene

The IDIBELL research group on Genes and Cancer led by Montse Sanchez-Cespedes discovered some years ago that the BRG1 gene, a tumour suppressor, is inactivated in non-small cell lung cancer by genetic mutations. "The BRG1 protein is part of a chromatin remodelling complex that regulates the expression of several genes", explains the researcher, "and it is related to the differentiation of lung cells, allowing cells response to certain hormones and environment vitamins like vitamin A or steroids."

When BRG1 is mutated and therefore inactive, tumour cells do not respond to the presence of these hormones and they continue growing and spreading. For this reason, these types of tumours are refractory to the treatment with these substances.

Clinic Application

"At the moment", says Montse Sanchez-Cespedes, "we are not able to restore the functionality of a tumour suppressor gene as BRG1 in patients. Therefore, we are still far from a therapeutic application but this discovery enables us to understand better the biology of tumours. What we will try to do in the immediate future is to look for agents that specifically destroy the cells with mutated BRG1, following the strategy of lethal synthetics".

In any case, this finding it can be useful in advancing personalized medicine, because "it explains why lung cancer patients are resistant to these treatments and may serve to rule out therapies with lipid-derived hormones in patients with BRG1 mutations, not just in lung cancer but also in breast and prostate, among others."


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related biology news :

1. Researchers discover gene mutations that cause childhood brain cancer
2. Penn biologists discover how silent mutations influence protein production
3. Rapid approach to identify influenza A virus mutations and drug resistance developed
4. Further gene mutations linked to autism risk
5. DNA mutations linked to diabetes
6. Species diversity helps ASU researchers refine analyses of human gene mutations
7. Study of huge numbers of genetic mutations point to oxidative stress as underlying cause
8. Penn biologists explain how organisms can tolerate mutations, yet adapt to environmental change
9. Mutations in different cells cooperate to set the stage for cancer
10. Supplement blocks the initiation of breast cell mutations by estrogens
11. Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... , ... June 21, 2016 , ... New light-based technologies ... into the tissue — promise to enable both compact, wearable devices for point-of-care diagnostics ... deeper under the skin. , Recent work and visionary future directions are detailed in ...
(Date:6/22/2016)... 22, 2016  Mesa Biotech Inc., a privately-held, ... platform designed specifically for point-of-care (POC) infectious disease ... advisory board (SAB). Approved by the executive leadership ... chartered to advise on the development and commercialization ... by Dr. Steve Young , this world-class ...
(Date:6/22/2016)... On Tuesday, June 21, 2016, the NASDAQ Composite ... Jones Industrial Average advanced 0.14% to finish at 17,829.73; and ... were broad based as five out of nine sectors ended ... following equities: Minerva Neurosciences Inc. (NASDAQ: NERV ), ... (NASDAQ: TRVN ), and Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:6/21/2016)... ... 21, 2016 , ... Three young scientists are being recognized for discovering novel ... with today’s announcement of the winners of the 2016 Blavatnik National Awards for ... Foundation and administered by the New York Academy of Sciences , honor the ...
Breaking Biology Technology: